PDirect Home | Quality at UVA | Clinical Trials | Find a Physician | Tools for your Practice | Referring to UVA | CME

COPD Certification | High Risk Clinic | New Cancer Clinical Trials | Stroke Center | External Iliac Arteriopathy

New Cancer Clinical Trials

Additional Trials Open Frequently at UVA

The University of Virginia Cancer Center offers many of the latest investigational treatments available for patients throughout Virginia, and is frequently opening new clinical trials. For a list of available cancer clinical trials categorized by type of cancer, click here.

Available trials include:

Breast Cancer: This National Cancer Institute-supported Phase I trial examines the combination of UCN-01 and irinotecan in women with triple negative (estrogen receptor negative, progesterone receptor negative, Her 2 negative), locally recurrent or metastatic breast cancer. UCN-01, a cell cycle inhibitor, is an investigational agent that arrests tumor cells. In our laboratory studies, we have shown that combination therapy increases the cytotoxicity of irinotecan. Women with no more than four prior chemotherapy regimens, including at least one anthracycline- and taxane-based regimen, are eligible. Principal Investigator: Paula M. Fracasso, MD, PhD; Study Coordinator: Mary Oliveri

Glioblastoma: This Phase II trial in conjunction with Dana-Farber Cancer Institute, M.D. Anderson Cancer Center and the University of California, San Francisco, is examining the effectiveness of XL184 for patients with glioblastomas who have failed first- or second-line treatment for glioblastoma. XL184 crosses the blood-brain barrier and inhibits multiple receptors that promote tumor cell growth. Patients must not have taken chemotherapy for 28 days; must not have taken phenytoin and carbamazepine for 14 days; and must not have acute intracranial or intratumoral hemorrhage. Principal Investigator: David Schiff, MD; Study Coordinator: Goga Radakovic

Multiple Myeloma: This Eastern Cooperative Oncology Group Phase III trial is examining the effectiveness of melphalan, prednisone, and thalidomide compared with melphalan, prednisone, and lenalidomide (RevlimidTM) in patients with multiple myeloma. Thalidomide and lenalidomide are approved agents for the treatment of multiple myeloma and will be compared in these oral treatment regimens. Patients must be newly diagnosed with multiple myeloma and age 65 or older or ineligible for stem cell transplantation. Principal Investigator: John J. Densmore, MD, PhD; Study Coordinator: Kimberly Underwood

To refer a patient to any of these trials, call UVA Physician Direct at 800.552.3723.